The Medical Device Advisory Panel (the Advisory Panel) under the Department of Health (DH) held its inaugural meeting today (November 19) to provide advice on a new statutory regulatory regime for medical devices that the Government is actively preparing to establish. The aim is to enhance the regulation of medical devices supplied in Hong Kong with respect to safety, quality and performance, thereby safeguarding public health, promoting orderly and sustainable development of the medical device industry, and developing Hong Kong into an international health and medical innovation hub.
The Advisory Panel is chaired by Professor Philip Chiu. Panel members are representatives from the medical, engineering, and innovation and technology sectors. A complete list of members is available on the website of the DH's Medical Device Division.
The First Five-Year Plan for Economic and Social Development of the Hong Kong Special Administrative Region (2026-2030) and The Chief Executive's 2026 Policy Address state that the Government will comprehensively intensify the regulatory reform of drugs and medical devices, enhance the regulatory regime, and establish the Centre for Medical Products Regulation. The Government is systematically advancing a number of initiatives, including taking forward legislative reform to establish a new statutory regulatory regime for medical devices that covers all aspects of risk management stages before and after medical devices are placed on the market. The DH aims to broadly and comprehensively gather valuable insights from various stakeholders through the Advisory Panel to establish a statutory regulatory framework for medical devices that is clear, practicable, forward-looking, tailored to Hong Kong's circumstances and aligned with international standards, thereby providing stronger institutional support for Hong Kong's development as an international health and medical innovation hub.
At the meeting, DH representatives presented the achievements of the current Medical Device Administrative Control System (MDACS), which has been operating for over 20 years on a voluntary basis, as well as the Government's legislative proposal on regulating medical devices in Hong Kong. The Advisory Panel fully supports the Government in advancing the relevant legislative work in accordance with the following key principles:
- to safeguard public safety and health;
- to promote innovation;
- to align with international regulatory standards;
- to build on the experience of the local administrative system;
- to focus on control at source and require upstream traders in the supply chain to obtain licences; and
- to implement tiered registration of medical devices in an orderly manner in accordance with the risk-based principle.
In addition to gathering and conveying stakeholders' feedback to the DH during the establishment of the statutory regulatory regime for medical devices, the Advisory Panel will also advise the DH on the operation and transitional arrangements of the MDACS.

